— Know what they know.
Not Investment Advice

AMPH NASDAQ

Amphastar Pharmaceuticals, Inc.
1W: -2.6% 1M: -2.5% 3M: +26.4% YTD: -3.7% 1Y: +3.0% 3Y: -43.2% 5Y: +33.8%
$25.57
+0.10 (+0.39%)
After Hours: $24.50 (-1.07, -4.18%)
Weekly Expected Move ±4.8%
$23 $24 $25 $26 $28
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 46 · $1.1B mcap · 31M float · 1.54% daily turnover · Short 72% of daily vol
Credit Risk of going bust: higher than 70% of companies Debt: 38.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.35 (down 95%), Amphastar Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $688.3M against a stock market value of $1.08B.
Distance to default 3.43 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $307.3M (short-term plus half of long-term), stock volatility 53.9%; Altman Z 2.15. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$1.6B +3.3% ▲
5Y CAGR: +20.9%
Total Liabilities
$840M -0.6% ▼
5Y CAGR: +35.7%
Shareholders Equity
$789M +7.7% ▲
5Y CAGR: +14.4%
Cash & Investments
$283M +27.6% ▲
5Y CAGR: +21.8%
Total Debt
$656M +0.8% ▲
5Y CAGR: +57.7%
Net Debt
$486M -2.6% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$126M$156M$144M$152M$170M
Short-Term Investments$10M$20M$113M$70M$113M
Cash & ST Investments$137M$176M$257M$222M$283M
Net Receivables$79M$89M$115M$138M$144M
Inventory$93M$104M$106M$154M$177M
Other Current Assets$3M$3M$11M$21M$33M
Total Current Assets$318M$378M$490M$534M$636M
Property, Plant & Equip.$271M$265M$316M$345M$354M
Goodwill & Intangibles$39M$37M$613M$591M$566M
Long-Term Investments$4M$2M$15M$11M$0
Other Non-Current Assets$17M$21M$26M$26M$31M
Total Non-Current Assets$353M$364M$1.0B$1.0B$993M
Total Assets$672M$742M$1.5B$1.6B$1.6B
— Liabilities —
Accounts Payable$22M$21M$25M$31M$33M
Short-Term Debt$2M$3M$436K$234K$2M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$23M$18M$0$0$0
Total Current Liabilities$104M$95M$225M$174M$158M
Long-Term Debt$74M$73M$590M$602M$609M
Other Non-Current Liab.$16M$15M$23M$21M$30M
Total Non-Current Liabilities$122M$118M$648M$671M$682M
Total Liabilities$226M$213M$873M$845M$840M
— Equity —
Common Stock$6K$6K$6K$6K$6K
Retained Earnings$180M$272M$409M$569M$667M
Accumulated OCI-$7M-$9M-$8M-$9M-$5M
Total Stockholders Equity$446M$529M$639M$732M$789M
Total Liabilities & Equity$672M$742M$1.5B$1.6B$1.6B
— Key Metrics —
Total Debt$105M$103M$624M$651M$656M
Net Debt-$22M-$54M$479M$499M$486M
Total Investments$14M$22M$128M$81M$113M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms